Can we use adenosine diphosphate (ADP) to study "aspirin resistance"? The Janus faces of ADP-triggered platelet aggregation.

Journal Title: Pharmacological Reports - Year 2008, Vol 60, Issue 3

Abstract

There is a growing number of contradictory reports indicating that adenosine diphosphate (ADP) can be a useful agonist in monitoring of the antiplatelet action of acetylsalicylic acid (ASA) in humans and animals. In the current study, we aimed to determine the conditions for using ADP to trigger platelet aggregation in order to detect ASA-mediated inhibition of rat platelet reactivity. Initially, we examined the usefulness of different ADP concentrations (0.25, 0.5, 1, 5 and 10 muM) in detecting the in vitro ASA mediated platelet inhibition using whole blood aggregometry, as well as we monitored the role of ADP in generation of thromboxane A(2) (TXA(2)). To study ex vivo ASA inhibitory potential on platelet aggregation induced by a range of ADP concentrations, animals were subjected to one or 10-day ASA administration at the dose of 50 mg/kg. Our experiment shows that ADP in a concentration-dependent manner induces TXA(2) generation in the whole blood with hirudin as an anticoagulant. However, in vitro and ex vivo examination of ASA inhibitory potential on platelet aggregation revealed that irrespectively of administration regimen, ASA failed to block platelet aggregation induced byADPat the concentrations higher than 0.5 muM. Our findings suggest that the mechanism of ADP-induced platelet aggregation depends on agonist concentration. It appears that only low ADP concentrations (up to 0.5 muM) induce TXA(2)-dependent rat platelet aggregation. Therefore, ADP could be considered a useful platelet agonist for monitoring of ASA-mediated platelet inhibition only if used at much lower concentrations than those commonly employed.

Authors and Affiliations

Marcin Dobaczewski, Jacek Golański, Tomasz Kowalski, Marek Nocuń, Barbara Kostka, Olga Ulicna, Miroslaw Mussur, Leszek Markuszewski, Cezary Watała

Keywords

Related Articles

Alpha(1) and alpha(2)-adrenoreceptor antagonists in streptozotocin- and vincristine-induced hyperalgesia.

The effect of alpha(1)- and alpha(2)-adrenoreceptor antagonists (prazosin and yohimbine, respectively) on streptozotocin (STZ)- and vincristine (VIN)-induced hyperalgesia in rats was studied. In two experimental models,...

Rimonabant attenuates sensitization, cross-sensitization and cross-reinstatement of place preference induced by nicotine and ethanol.

The present study focused on the evaluation of behavioral sensitization, cross-sensitization, and cross-reinstatement processes induced by nicotine and ethanol in rodents. First, we showed that nicotine (0.175 mg/kg, bas...

Effect of neuraminidase treatment on persistent epileptiform activity in the rat hippocampus.

Negatively charged sialic acid residues located close to pores of voltage-gated sodium channels substantially influence their gating properties. The in vitro low Mg(2+) seizure model is used to emulate difficult-to-treat...

Impact of ursolic acid on chronic ethanol-induced oxidative stress in the rat heart.

Oxidative stress plays an important role as a mediator of myocardial damage produced by ethanol. This work was designed to investigate the effect of ursolic acid (UA), a reported radical scavenger and antioxidant, on oxi...

Effects of sildenafil treatment on the development of tolerance to diazepam-induced motor impairment and sedation in mice.

We studied the effects of sildenafil, a selective inhibitor of PDE5, on the development and the expression of tolerance to diazepam (DZ)-induced motor impairment and sedation in mice. DZ-induced motor incoordination was...

Download PDF file
  • EP ID EP118548
  • DOI -
  • Views 90
  • Downloads 0

How To Cite

Marcin Dobaczewski, Jacek Golański, Tomasz Kowalski, Marek Nocuń, Barbara Kostka, Olga Ulicna, Miroslaw Mussur, Leszek Markuszewski, Cezary Watała (2008). Can we use adenosine diphosphate (ADP) to study "aspirin resistance"? The Janus faces of ADP-triggered platelet aggregation.. Pharmacological Reports, 60(3), 361-368. https://europub.co.uk/articles/-A-118548